Cognitive•Anxiolytic
🧠Selank
Anxiolytic nootropic peptide developed in Russia. Modulates GABA-A, BDNF, and IL-6. Reduces anxiety without sedation or addiction potential. Approved in Russia for anxiety and phobia treatment.
Amino acids
7
Mol. weight
751.9 Da
Half-life
~2 minutes (intranasal active)
Availability
On inquiry
Amino acid sequence
Thr-Lys-Pro-Arg-Pro-Gly-ProWhat Is Selank?
Selank is a synthetic heptapeptide analogue of the endogenous tetrapeptide tuftsin. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Approved in Russia for the treatment of generalized anxiety disorder and phobia. It demonstrates anxiolytic effects without the sedation, dependence, or withdrawal of benzodiazepines.
Key Mechanisms
- GABA-A modulation — enhances GABAergic tone without direct benzodiazepine site binding
- BDNF upregulation — increases brain-derived neurotrophic factor; neuroprotective and neuroplasticity effects
- IL-6 modulation — anti-inflammatory effects in CNS; reduces neuroinflammatory markers
- Enkephalin metabolism regulation — prolongs endogenous opioid peptide activity
Key References
- Zozulia AA et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders." Zh Nevrol Psikhiatr Im SS Korsakova, 2008;108(4):38–48.
Related in Cognitive
🧠Neuroprotective
Cerebrolysin
Brain-derived neurotrophic peptide mixture approved in 50+ countries for Alzheimer's, stroke and TBI. Neurotrophic, neuroprotective and neuroregenerative effects mediated through BDNF, NGF and GDNF pathways.
🧠Cognitive Research
Dihexa
HGF/MET signalling enhancer. Reported to be 7 orders of magnitude more potent than BDNF at inducing synaptogenesis. Blood-brain barrier penetrant. Used in dementia and cognitive decline research.
🧠Nootropic
Semax
ACTH-derived nootropic peptide. Upregulates BDNF and NGF. Approved in Russia for ischemic stroke, TBI, optic nerve atrophy, and ADHD. Enhances memory, focus and neuroprotection.